Tariff worries pushed the ASX down, coal took a hit after Macquarie's call, while gold climbed as the market edged closer to ...

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy ... including Denmark and Ireland. "Today’s approval brings us closer to our ultimate goal of providing ...

Orkambi O (ivacaftor, lumacaftor) Vertex Pharmaceuticals (Canada ... Ravicti O (glycerol phenylbutyrate) Horizon Pharma Ireland Ltd - Ravicti is used as a nitrogen-binding agent for chronic management ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $495.42 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Let's take a closer look at a couple of our picks from the screened companies. Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing ...

Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its ...